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Introduction: Preeclampsia is a complex and heterogeneous disease with increased risk of maternal
mortality, especially for earlier gestational onset. There is a great inconsistency regarding the genetics of
preeclampsia across the literature. The gene Activin A receptor, type IIA (ACVR2A), was reported as
associated to preeclampsia in Australian/New Zealand and Norwegian populations. The goal of this study
was to validate this genetic association in a Brazilian population.
Methods: We performed a case-control study using 693 controls and 613 cases (443 preeclampsia, 64
eclampsia and 106 HELLP syndrome), from a Northeastern Brazilian population. Five single nucleotide
polymorphisms (SNPs) in ACVR2A were tested for association through multiple logistic regression
models.
Results: There was no statistical association with preeclampsia (per se), eclampsia or HELLP. However, by
grouping preeclampsia in accordance to the gestational age at delivery, SNPs rs1424954 (OR ¼ 1.86; 95%
CI, 1.25e2.78; p ¼ 0.002) and rs1014064 (OR ¼ 1.77; 95% CI, 1.21e2.60; p ¼ 0.004) were signiﬁcantly
associated with early onset preeclampsia (gestational age  34 weeks). The risk haplotype had a fre-
quency of 0.468 in early preeclampsia compared to 0.316 in controls (p ¼ 0.0008 and permuted
p ¼ 0.002).
Discussion: Activin A receptors are important in decidualization, trophoblast invasion and placentation
processes during pregnancy. The gene ACVR2A was associated with the more severe early onset pre-
eclampsia. This ﬁnding supports the hypothesis of different pathogenic mechanisms contributing to the
early- and late-onset preeclampsia.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Preeclampsia is a pregnancy-related hypertensive disorder and
a leading cause of maternal and infant mortality. It complicates
2e8% of pregnancies worldwide with rates of this disease reaching
17% in developing countries [1,2]. Generally, preeclampsia is
deﬁned as de novo proteinuria and hypertension after 20 weekstry and Institute of Tropical
of Rio Grande do Norte, Av.
2 2286.
.gestation. Gestational age of onset can be considered in the severity
of preeclampsia [3], with early onset (34.0 weeks gestation)
associated with increased maternal complications and mortality
while late-onset (>34.0 weeks gestation) are often secondary to
other co-morbidities, like obesity [4,5].
Preeclampsia is shown to aggregate in families, suggesting
genes may inﬂuence outcome [6e8], however this mechanism re-
mains unclear. The genetic architecture behind preeclampsia is
complex, including environmental factors, maternal and fetal
genes, and their combined effects (i.e. interaction between paternal
and maternal genes) [9]. Five genome-wide linkage studies
[10e14], two genome-wide association studies [15,16] and several
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ciated to preeclampsia.
ACVR2A encodes activin A type II receptor (ActRIIA) which, along
with Activin A receptor, type IB (Alk-4), plays an important role in
the establishment of pregnancy, especially during decidualization,
trophoblast invasion and placentation processes [18]. There is
increasing evidence that Activin A and its receptors, including
ActRIIA, are involved in preeclampsia pathophysiology [19,20]. The
ACVR2A gene has been implicated in susceptibility to developing
preeclampsia in Australian/New Zealand family studies [21,22].
Additionally, an independent Norwegian population-based study
identiﬁed an association between single nucleotide poly-
morphisms (SNPs) in ACVR2A and preeclampsia [23]. In this study,
we aimed to validate the genetic association between ACVR2A and
preeclampsia in a northeastern Brazilian population in Natal, Brazil.
2. Material and methods
2.1. Participants and study design
A total of 1306 women (693 controls and 613 cases) were recruited at a referral
center for high-risk pregnancy (Maternidade Escola Januario Cicco) in Natal, State of
Rio Grande do Norte, Brazil, from 2001 to 2012. High-risk pregnant women are sent
to this center from across the region for evaluation and medical treatment. Clinical
data were collated from patients' charts at the time of enrollment.
2.2. Ethical considerations
The protocol was reviewed and approved by the Federal University of Rio
Grande do Norte (CEP-UFRN 88) and Brazilian National Ethical Committee (CONEP
5059). All participants or their legal guardian provided informed consent.
2.3. Phenotype deﬁnition
Preeclampsia was deﬁned as a pregnant woman with de novo hypertension
(systolic blood pressure (SBP)  140 mmHg or diastolic blood pressure
(DBP)  90 mmHg) and proteinuria after 20 weeks of gestation. For those women
missing proteinuria information, we looked for one or more of the following
symptoms: severe epigastric or right upper quadrant pain; hypereﬂexia with sus-
tained clonus; severe headache; persistent visual disturbances; pulmonary edema;
fetal growth restriction; placental abruption [24]. Eclampsia was deﬁned as the
occurrence of seizures in preeclamptic women while HELLP syndrome was deﬁned
in accordance to the Mississippi-Triple Class System: AST or ALT  40 IU/L;
LDH  600 IU/L and platelets  150  109/L [25]. Based on these criteria, a total of
443 women had preeclampsia, including 61 chronic hypertension with super-
imposed preeclampsia; an additional 64 had eclampsia and 106 had HELLP syn-
drome (Table 1). Diagnoses were determined by trained physicians at the Maternity
Hospital (Maternidade Escola Januario Cicco, Natal, RN, Brazil) and all clinical and
laboratorial data were individually reviewed by the study investigators in order to
assure consistent criteria in accordance with the American College of Obstetricians
and Gynecologists [26].
The gestational age at delivery was used as a proxy for gestational age of onset
for early cases since all preeclampsia (PE) deliveries before 34 weeks would also
have onset before 34 weeks. There is the potential for some misclassiﬁcation of the
late gestational age cases as a proxy for onset, since some of the late PE gestational
age cases may have presented with early onset but were able to delay deliveryTable 1
Demographics and clinical features for the phenotypic groups.
Variables Control
N ¼ 693
Maternal age, years 24.4 (±6.2)
Primigesta, n (%) 300 (43.3)
Chronic hypertension, n (%) 0 (0.0)
Systolic blood pressure, mmHg 117 (±12)
Diastolic blood pressure, mmHg 75 (±9)
Proteinuria (dipstick)
Negative, n (%) 693 (100)
 1þ, n (%) 0 (0.0)
Missing, n (%) 0 (0.0)
Gestational age at delivery, week 38.8 (±3.1)
Infant's birth weight, grams 3143 (±634)
For continuous variables, mean (±SD) were estimated. Two-sided Fisher exact test was
compare means.
ap value 0.05 for the comparison with control group.because of less severity. Preeclampsia cases were grouped into either early PE (34.0
weeks' gestation) or late PE (>35.0 weeks' gestation) categories. Preeclamptic
women who were greater than 34 weeks but less than or equal to 35 weeks at
gestational delivery were excluded (n ¼ 31), in order to avoid misclassiﬁcation due
to imprecision when assessing gestational age. In addition, we also excluded 21
cases of preeclampsia from the analysis of time of onset the disease, because of
missing information regarding the gestational age; therefore, the sample considered
in Table 3 includes 391 cases. Controls were pregnant womenwho had normal blood
pressure and no previous history of hypertension or preeclampsia and were from
the same socio-economic background as the cases. Cases and controls with
multiple-birth pregnancies, diabetes, kidney and/or heart disease were excluded
from the study.
2.4. DNA extraction and genotyping
At the time of enrollment, 8 ml of anticoagulated whole blood (EDTA) was
collected by venipuncture. DNA was extracted by erythrocyte lysis in 0.87 mM
NH4H2CO3 and 0.13 M NH4Cl followed by lysis of leukocytes in 1% sodium dodecyl
sulfate, 100 mM EDTA, and 200 mM Tris (pH 8.5). Proteins were removed by pre-
cipitation with ammonium acetate 5 M. DNAwas precipitated from the supernatant
by isopropanol, followed by wash with 70% ethanol. DNA was solubilized in 500 mL
of TE (Tris-EDTA) buffer and stored at 20 C until genotyping assay.
Samples were genotyped by SNaPshot® technique and the capillary electro-
phoresis performed on ABI PRISM® 3100 Avant Genetic Analyzer (Applied Bio-
systems). This technique standardizationwas carried out according to Lins et al. [27].
Genotyping was done in a blind way for case-control status. GeneMapper® software
v3.5 (Applied Biosystems, CA, USA) was used for the genotype calling.
2.5. Genetic markers selection
We selected 5 SNPs in or near the ACVR2A gene. SNP rs1424954, located 50 to the
ACVR2A gene (z1.8 kb from the transcription start site), was associated with pre-
eclampsia in a family-based study [21]. SNPs rs2161983, rs1014064, rs1424941 and
rs3768687, located in intronic regions, were associated with preeclampsia in a
population-based candidate gene study [23]. Fig. 1 shows the ACVR2A genetic or-
ganization and SNP positions (Assembly, reference; Genome build, 36.3).
2.6. Population stratiﬁcation assessment
The Brazilian population is composed of Europeans (predominantly Portu-
guese), western Africans and Native Brazilians. Confounding by ethnicity or popu-
lation stratiﬁcation may arise when allele frequencies and disease risk vary across
ancestries. We randomly selected 756 individuals (Supplementary Table 1) and
genotyped a panel of 27 ancestry informative markers designed to infer genetic
ancestry in a Brazilian population [28]. Genotyping for this ancestry panel was
performed by LGC Genomics (UK). We used principal components analysis (PCA) in
Eigenstrat [29] to assess the populations and no stratiﬁcation was detected
(Supplementary Fig. 1).
2.7. Statistical analysis
Categorical variables were analyzed using two-sided Fisher's exact test;
continuous variables were analyzed using Student's t-test. To assess the genetic
association of ACVR2A markers, odds ratios (OR) were estimated by multinomial
logistic regression comparing preeclampsia (early and late gestational age),
eclampsia and HELLP outcomes with the normal pregnancy outcome (controls).
Genotypes were coded as 0, 1 and 2 according to the number of minor alleles under
an additive geneticmodel. Maternal age, parity (primigravida vs. others) and chronic
hypertension affection status were included in the model as covariates. StatisticalPreeclampsia
N ¼ 443
Eclampsia
N ¼ 64
HELLP
N ¼ 106
25.9 (±7.1)a 20.7 (±6.6)a 27.6 (±6.8)a
217 (49.0) 45 (70.3)a 41 (38.7)
61 (13.8) 2 (3.1) 10 (9.4)
158 (±22)a 158 (±18)a 154 (±20)a
106 (±14)a 108 (±13)a 102 (±12)a
0 1 (1.6) 9 (8.5)
386 (87.1) 47 (73.4) 90 (84.9)
57 (12.9) 16 (25.0) 7 (6.6)
37.0 (±3.2)a 36.1 (±3.7)a 34.1 (±4.2)a
2735 (±838)a 2568 (±809)a 1949 (±778)a
used to compare the distribution of categorical variables and two-sided t-test to
Table 2
Genetic association of ACVR2A SNPs with preeclampsia per se, eclampsia and HELLP syndrome phenotypes.
SNP Minor allele Control
n ¼ 693
Preeclampsia
n ¼ 443
Eclampsia
n ¼ 64
HELLP
n ¼ 106
MAF MAF OR (95% CI) p MAF OR (95% CI) p MAF OR (95% CI) p
rs1424954 A 0.311 0.352 1.18 (0.97e1.45) 0.11 0.352 1.18 (0.78e1.77) 0.44 0.275 0.82 (0.58e1.17) 0.28
rs1014064 G 0.313 0.351 1.19 (0.98e1.44) 0.08 0.336 1.12 (0.75e1.69) 0.57 0.282 0.86 (0.61e1.22) 0.41
rs1424941 T 0.156 0.146 0.90 (0.70e1.15) 0.46 0.133 0.81 (0.47e1.41) 0.46 0.144 0.91 (0.59e1.39) 0.66
rs2161983 A 0.324 0.356 1.13 (0.93e1.38) 0.22 0.328 1.00 (0.67e1.51) 0.97 0.281 0.82 (0.58e1.16) 0.26
rs3768687 T 0.317 0.342 1.10 (0.91e1.34) 0.26 0.328 1.04 (0.69e1.58) 0.82 0.283 0.85 (0.60e1.20) 0.36
Odds ratio (OR) was estimate bymultinomial logistic regressionmodel (control as reference group), adjusting for maternal age, parity and chronic hypertension status using an
additive genetic model. MAF: minor allele frequency.
Table 3
Genetic association of ACVR2A SNPs with early onset preeclampsia.
SNP Minor allele Control
n ¼ 693
Late preeclampsia
n ¼ 321
Early preeclampsia
n ¼ 70
MAF MAF OR (95% CI) p MAF OR (95% CI) p
rs1424954 A 0.31 0.33 1.08 (0.87e1.36) 0.476 0.46 1.86 (1.25e2.78) 0.002
rs1014064 G 0.31 0.33 1.10 (0.88e1.36) 0.401 0.45 1.77 (1.21e2.60) 0.004
rs1424941 T 0.16 0.14 0.88 (0.67e1.17) 0.376 0.16 1.03 (0.62e1.71) 0.914
rs2161983 A 0.32 0.34 1.05 (0.84e1.30) 0.680 0.46 1.70 (1.15e2.53) 0.008
rs3768687 T 0.32 0.33 1.03 (0.83e1.28) 0.769 0.42 1.52 (1.02e2.26) 0.039
Odds ratio (OR) was estimate by multinomial logistic regression model (control as reference group), adjusting for maternal age, parity and chronic hypertension status.
MAF: minor allele frequency.
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pattern among markers was assessed by pairwise correlation coefﬁcient (r2) esti-
mates using Haploview 4.2 [30]. Haplotype frequencies were estimated via EM al-
gorithm and tested for association through logistic regression model implemented
in PLINK [31]. The p-values were estimated by max (T) permutation (n ¼ 10,000) in
PLINK, which controls for family wise error rate.
3. Results
3.1. Demographics and clinical features
The demographic and clinical characteristics among the groups
are shown in Table 1. Preeclamptic women were older than the
control women (mean age, 25.9 vs. 24.4) and had the highest
prevalence of chronic hypertension (13.8%).Womenwith eclampsia
were younger at delivery (mean age ¼ 20.7) with the highest
proportion of primigravidas (70.3%), whereas women with HELLP
syndrome were the oldest at delivery (mean age ¼ 27.6). HELLPFig. 1. Linkage disequilibrium (LD) pattern and the schematic localization of the ﬁve geno
scheme. Black squares represent r2 > 0.8 and the light gray squares r2 < 0.1. The inside-
rs1014064, rs2161983 and rs3768687 are in strong LD with each other (r2 > 0.9).syndrome cases had the earliest intervention, usually cesarean
section, in order to decrease infant mortality and maternal
morbidity, but this resulted in lower infant birth weight (Table 1).
3.2. Genetic analysis
All studied SNPs achieved a genotyping call rate 94% and were
in HardyeWeinberg equilibrium (p > 0.05). The schematic of the
ACVR2A gene and the LD pattern among genotyped SNPs are shown
in Fig. 1. The SNPs rs1424954, rs1014064, rs2161983 and rs3768687
were in strong pairwise LD (D0 > 0.95; r2 > 0.9). However,
rs1424941 was poorly correlated with the other four SNPs
(r2 ¼ 0.08). This same LD pattern was observed in both Australian
and Norwegian populations [22,23].
The ﬁve SNPs showed no associationwith preeclampsia (per se),
eclampsia or HELLP syndrome (Table 2). However, markers
rs1014064 (OR¼ 1.77; p¼ 0.004), rs1424954 (OR¼ 1.86; p¼ 0.002)typed ACVR2A SNPs. The Haploview 4.2 software created a LD plot using the r2 color
square number represents the correlation coefﬁcient value. The markers rs1424954,
Table 4
Haplotype association tests using logistic regression model.
Haplotypea Haplotype frequency OR p-value Permuted
p-value
Control Early PE
A/G/C/A/T 0.316 0.468 1.86 0.0008 0.002
G/A/T/G/C 0.161 0.158 0.95 0.8288 0.987
G/A/C/G/C 0.524 0.374 0.50 0.0004 0.001
a The alleles composing the haplotypes refer to the respective markers:
rs2161983/rs1014064/rs1424941/rs1424954/rs3768687.
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the more severe early onset preeclampsia (Table 3). The underlying
linkage disequilibrium between these SNPs suggest that thesewere
not independent associations, but represent the same signal.
Therefore, we estimated the haplotypes in this gene region for
these SNPs. The haplotype including the signiﬁcant minor alleles
increased the risk to early PE whereas the haplotype composed by
the major alleles was protective (Table 4). Since the haplotype as-
sociation was more signiﬁcant than the individual SNPs, this sug-
gests that the causal allele is within this haplotype block. These
statistical associations are robust to a Bonferonni correction for
multiple testing using a threshold of p < 0.01. In addition, by
considering chronic hypertension with superimposed preeclamp-
sia apart from purely preeclampsia cases, we found that ACVR2A
SNPs remained speciﬁcally associated with early onset pre-
eclampsia (Supplementary Table 2). Finally, by grouping all 613
cases (n¼ 443 preeclampsia; n¼ 64 eclampsia; and n¼ 106 HELLP)
no association was found (p > 0.1) (data not shown). Although we
did not detect population stratiﬁcation in this studied population,
we recognize that Brazilian population is highly admixed and there
may be inﬂated associations due to population confounding. Thus,
we evaluated the association in a subset of the population with
available ancestry informative markers, and the association
remained for SNPs rs1424954 and rs1014064, after adjusting for the
ﬁrst three principal components (Supplementary Table 3).
4. Discussion
Activin A receptors are important in decidualization, tropho-
blast invasion and placentation processes during pregnancy.
Studies in European ancestry populations show an association of
Activin A receptor, type IIA (ACVR2A) with preeclampsia [21,23]. In
the present study, we successfully validated the association be-
tween ACVR2A gene and preeclampsia in a population from
northeast Brazil. An important caveat to our study is that the ge-
netic association was detected only in early onset preeclampsia.
Interestingly, neither eclampsia nor HELLP syndrome were associ-
ated with ACVR2A, suggesting distinct genetic mechanisms under-
lying hypertensive disorders of pregnancy.
The genetic association with ACVR2A and preeclampsia is not
clear with some studies ﬁnding genetic associations and others
failing to see an association. Moses et al., were the ﬁrst to report the
genetic association of ACVR2A (rs1424954) with preeclampsia in 34
Australian/New Zealand families [21], but this ﬁnding was not
replicated in a second study when 40 additional families were
included [22]. More recently, Lokki et al. failed to replicate the
genetic association between rs1424954 and preeclampsia in a
Finnish population [32]. Roten et al. found an association with
ACVR2A in the SNPs rs2161983, rs1014064, rs1424941 and
rs3768687 in a large Norwegian population-based study [23]. Un-
like our study, those studies [21e23,32] did not take into account
the time of disease onset. Besides differences in sample size and
case ascertainment scheme, characteristics of each population may
contribute to the differences observed among the genetic studiesand this may include environmental factors (e.g. life style, health
care system, social-economic and educational features) that could
modify the genetic effect of ACVR2A variants. Australian/New Zea-
land, Norwegian, Finnish and Brazilian populations have distinct
ancestry and, therefore, it is reasonable that there may be differ-
ences underlying the LD pattern within this gene region among
these populations. In addition, genetic heterogeneity may cause
variation in the association strength across studies and it is likely
that other genes, in addition to ACVR2A, could also be responsible
for some of these preeclampsia cases.
The role of activin receptors and its ligands (e.g. activins and
inhibins) on healthy and pathological pregnancies have been well
documented. Several studies have reported higher levels of activin
A in serum of preeclamptic women when compared to normal
pregnancies [20,33] and, recently, it was shown that preeclamptic
placentas expressing high levels of activin A induce trophoblast cell
apoptosis via Nodal/ALK7 signaling [34]. Manuelpillai and col-
leagues showed that the amount of activin A and ActRII in placenta
and choriodecidua, respectively, differed in early- and late-onset
preeclampsia [19]. In addition, the mRNA expression level of acti-
vin A receptor, type I (ACVR1) was elevated in the decidua of early
preeclamptic placentas [35]. Lastly, it was detected a remarkable
difference between early and late preeclamptic placentas, by both
global gene expression proﬁle [36e38] and histopathology [39].
Altogether, these ﬁndings support our hypothesis that poly-
morphisms in ACVR2A may disrupt placentation leading to the
early-onset preeclampsia.
In conclusion, we showed that the ACVR2A gene is associated
with early onset preeclampsia. The association between ACVR2A
and preeclampsia in three unrelated populations (Australian/New
Zealand, Norwegian and Brazilian) suggests an important role of
this gene in the preeclampsia etiology. In addition, our ﬁnding also
supports the hypothesis of different pathogenic mechanisms un-
derlying the late- and early-onset forms of the disease as well as
distinct genetic mechanisms behind preeclampsia, eclampsia and
HELLP syndrome.
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